Trial Profile
Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms ABEPSA-BB
- 02 Oct 2022 Status changed from recruiting to discontinued.
- 17 May 2018 New trial record